Home›Research›Compare›Angiotensin (1-7) vs Retinalamin
Peptide ComparisonAngiotensin (1-7) vs Retinalamin
Both are Longevity & Cellular peptides.
Angiotensin (1-7)
Ang-(1-7)
Half-life: ~9–10 sec (rat)
No providers listed yet
Retinalamin
Retinal bioregulator
Half-life: Unknown
1 providers listed
Angiotensin (1-7) carries stronger published evidence (RCT, 15 key studies) than Retinalamin (Review, 2); both are research compounds.
Angiotensin (1-7)
Evidence
Half-life
~9–10 sec (rat)
Retinalamin
Evidence
Half-life
Unknown
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Angiotensin (1-7) |
| Further along in FDA review | Angiotensin (1-7) |
| More provider options (0 vs 1) | Retinalamin |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Angiotensin (1-7)
Retinalamin
Angiotensin (1-7)
The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.
Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…
Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.
Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the re…
+11 more
Retinalamin
Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium
Bioavailability and Biological Activities of Food-Derived Di- and Tripeptides: In Silico and In Vitro Studies
About Angiotensin (1-7)
Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.
About Retinalamin
Polypeptide bioregulator from bovine retina; normalizes retinal pigment epithelial and photoreceptor cell function; reduces oxidative damage in retinal tissue
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Angiotensin (1-7)
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Retinalamin
No established clinical contraindications
Where to source these peptides
Angiotensin (1-7)
Browse directory →
Providers offeringRetinalamin
1 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.